Fig. 6: Upregulation of CCR2 confers regorafenib resistance to CRC cells in vivo. | Cell Death & Disease

Fig. 6: Upregulation of CCR2 confers regorafenib resistance to CRC cells in vivo.

From: A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer

Fig. 6: Upregulation of CCR2 confers regorafenib resistance to CRC cells in vivo.

a Representative images of xenografts formed by injection of nude mice with tumor cells, followed by regorafenib (Reg) or vehicle (Veh) treatment. b Growth curves and average weight of subcutaneous xenografts formed in nude mice. c IHC staining of β-catenin and Ki-67 in the tissues of xenografts. Scale, 50 μm. d Schematic illustration of the mechanism by which CCR2 promotes CRC cells resistance to regorafenib

Back to article page